After the close, GW Pharma (NASDAQ: GWPH) issued two press releases and hosted a conference call to review its FY18-Q1 ending 12/31/17. The company reported that the European Medicines...

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex(R) (cannabidiol) Study in The Lancet First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare,...

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome...

Earlier this week, we highlighted a story published on Leafly regarding lobbying efforts by GW Pharma (NASDAQ: GWPH). Leafly’s Bruce Barcott discovered that GW Pharma and its U.S. subsidiary,...

Note: We published a follow up to this article Leafly’s Bruce Barcott has uncovered some actions taken by GW Pharma (NASDAQ: GWPH) that appear to be part of an...

GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting –  Presentations include clinical results from Phase 3 programs in...